{
    "clinical_study": {
        "@rank": "164936", 
        "arm_group": [
            {
                "arm_group_label": "Arhalofenate 600 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arhalofenate 800 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Allopurinol 300 mg; colchicine 0.6 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Allopurinol 300 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether arhalofenate is effective in preventing\n      flares and reducing serum uric acid in gout patients."
        }, 
        "brief_title": "Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gout", 
        "condition_browse": {
            "mesh_term": "Gout"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients between 18 and 75 years of age, inclusive\n\n          -  Known gout diagnosis (per criteria of the American Rheumatism Association for the\n             classification of the acute arthritis of primary gout, see Appendix 3)\n\n          -  At least three patient-reported and documented flares during the 12 months prior to\n             screening (the first of these flares may have resulted in the gout diagnosis; any\n             recent flare must have resolved, with the patient back to usual comfort level at\n             least seven days prior to screening)\n\n          -  Have not used any ULT since at least two weeks prior to screening\n\n          -  Have not used colchicine since at least two weeks prior to screening\n\n          -  Usual level of resting pain when NOT experiencing flare is three or less on an\n             11-point numerical rating scale (NRS)\n\n          -  Have a sUA \u2265 7.5 mg/dL and \u2264 12 mg/dL at screening\n\n          -  All female patients must be surgically sterile or post-menopausal (at least 45 years\n             of age with no history of menses for at least two years); or have a partner who has\n             undergone vasectomy or must agree to use two medically accepted methods of\n             contraception including a barrier method (see Appendix 4) for the entire duration of\n             study participation unless she reports complete sexual abstinence. Female patients\n             must not be pregnant or lactating\n\n          -  Estimated creatinine clearance (eCrCl) \u2265 60 ml/min/1.73m2 calculated by\n             Cockcroft-Gault method at screening\n\n          -  Liver function tests \u2264 3X ULN for AST, ALT and total bilirubin; \u2264 3X ULN for ALP and\n             GGT; and \u2264 3X ULN for CK at screening\n\n          -  All other clinical laboratory parameters must be within normal limits or considered\n             not clinically significant\n\n          -  Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically\n             significant at screening\n\n          -  Systolic blood pressure \u2264 160 mm Hg and diastolic blood pressure \u2264 90 mm Hg at\n             screening; known hypertensive patients stable (blood pressure [BP] reading as above)\n             with medication may be included\n\n          -  Patients using agents known to influence sUA levels (see Appendix 7) must be on a\n             stable dose and regimen for at least two weeks prior to screening and must be willing\n             to continue the same doses and regimens during study participation\n\n          -  Expected to be able to tolerate a short course of either oral NSAIDs and/or oral\n             steroids as may be needed to treat a flare\n\n          -  Must be able to swallow tablets/capsules\n\n          -  Following training, must be willing and able to understand and complete an electronic\n             diary\n\n        Exclusion Criteria:\n\n          -  Receiving treatment with allopurinol, colchicine, probenecid, benzbromarone, or\n             febuxostat within two weeks or pegloticase within six months prior to screening\n\n          -  Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder\n             or organ transplant)\n\n          -  Diagnosis of xanthinuria\n\n          -  Fractional excretion of urate > 10% at screening\n\n          -  History of documented or suspected kidney stones\n\n          -  Known infection with the human immunodeficiency virus (HIV) or history of viral\n             hepatitis type B or C\n\n          -  A diagnosis of illicit drug or alcohol dependence or abuse within one year of\n             screening\n\n          -  History of upper gastrointestinal (GI) bleeding, documented peptic ulcer disease\n             (unless known H. pylori infection treated successfully without recurrence), within\n             three years of screening\n\n          -  History of stroke, transient ischemic attack (TIA), acute myocardial infarction (MI),\n             congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention\n             procedure (including but not limited to angioplasty, stent placement, coronary\n             revascularization), lower extremity bypass procedure, systemic or intracoronary\n             fibrinolytic therapy within five years of screening\n\n          -  History of cancer within five years of screening, with the following exceptions:\n             adequately treated non-melanomatous skin cancers,  non-metastatic prostate cancer or\n             in situ cervical cancer\n\n          -  Patients with a history of bladder cancer, active bladder cancer or hematuria\n\n          -  Body mass index (BMI) > 42 kg/m2 at screening\n\n          -  Current or expected requirement for anticoagulant therapy (except for aspirin \u2264 325\n             mg/day, clopidogrel [Plavix] \u2264 75 mg/day, or prasugrel [Effient] \u2264 10 mg/day)\n\n          -  Use of any of the following within eight weeks prior to screening: potent CYP3A4\n             inhibitors, cytotoxic agents (including azathioprine, mercaptopurine, cyclosporine,\n             cyclophosphamide, etc.), ranolazine, digoxin, theophylline, sulphonylureas,\n             thiazolidinediones (e.g., rosiglitazone or pioglitazone), atypical antipsychotic\n             agents, ampicillin, amoxicillin, loop diuretics or phenytoin\n\n          -  Chronic treatment with NSAIDs (except for as needed [prn] use to treat acute events);\n             per protocol a short course of oral NSAIDs may be used to treat flares during the\n             study\n\n          -  Current or expected chronic treatment with systemic corticosteroids (topical,\n             ophthalmic, intra-articular or inhaled corticosteroid at a dose < 1600 \u03bcg/day is\n             permitted); per protocol a short course of oral corticosteroid may be used to treat\n             flares occurring during the study\n\n          -  History of intra-articular steroid injection to treat flare within four weeks of\n             screening\n\n          -  Known hypersensitivity or intolerance to allopurinol or colchicine\n\n          -  Treatment with any other investigational therapy within 30 days or within five half\n             lives, whichever is longer, prior to screening\n\n          -  Patients who received arhalofenate in a previous trial\n\n          -  Any other condition(s) that would compromise the safety of the patient, prevent\n             compliance with the study protocol including ability to use an electronic diary, or\n             compromise the quality of the clinical study, as judged by the Investigator and/or\n             Medical Monitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "225", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063997", 
            "org_study_id": "CB102-21425"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arhalofenate 600 mg", 
                "description": "Arhalofenate 600 mg tablets once daily for 12 weeks", 
                "intervention_name": "Arhalofenate 600 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Allopurinol 300 mg; colchicine 0.6 mg", 
                    "Allopurinol 300 mg"
                ], 
                "description": "Allopurinol 300 mg tablets once daily for 12 weeks", 
                "intervention_name": "Allopurinol 300 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Allopurinol 300 mg; colchicine 0.6 mg", 
                "description": "Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks", 
                "intervention_name": "Colchicine 0.6 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablets once daily for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arhalofenate 800 mg", 
                "description": "Arhalofenate 800 mg tablets once daily for 12 weeks", 
                "intervention_name": "Arhalofenate 800 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Allopurinol", 
                "Colchicine", 
                "Uric Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DeLand", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jupiter", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Port Richey", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Harbor", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boise", 
                        "country": "United States", 
                        "state": "Idaho"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brownsburg", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bowling Green", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elizabethtown", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Owensboro", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hagerstown", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olive Branch", 
                        "country": "United States", 
                        "state": "Mississippi"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Missoula", 
                        "country": "United States", 
                        "state": "Montana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hickory", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salisbury", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johnstown", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wyomissing", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingsport", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Jordan", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clarksburg", 
                        "country": "United States", 
                        "state": "West Virginia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newmarket", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarnia", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tbilisi", 
                        "country": "Georgia"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Georgia"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients", 
        "other_outcome": [
            {
                "measure": "Proportion of patients experiencing at least one flare from baseline through Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of patients experiencing two or more flares from baseline through Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The incidence of flares from baseline through Week 4, from Week 5 through Week 8, and from Week 9 through Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Duration of flares", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Duration of flare treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Flare composite score (summation of the daily maximum pain score on NRS during the duration of the flare)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of patients experiencing flares who reached a sUA target < 6 mg/dL during treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Evaluation of activity limitation associated with flare via HAQ-II", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes from baseline in fractional excretion of urate", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes from baseline in HbA1c and fasting TG in patients with HbA1c > 7.0% and TG > 150 mg/dL at baseline, respectively", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Adverse events (AE), and changes in vital signs and safety laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Safety-related study drug discontinuations", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Flare-related study drug discontinuations", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Steady-state arhalofenate acid serum and urine concentrations", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_contact": {
            "email": "pboudes@cymabay.com", 
            "last_name": "Pol Boudes, MD", 
            "phone": "510-293-8815"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Georgia: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063997"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent sUA reduction from baseline to Week 12 in the arhalofenate 800 mg group compared to the placebo group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Percent sUA reduction from baseline to Week 12 in the arhalofenate 600 mg group compared to the placebo group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 800 mg group compared to the placebo group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The incidence of flares from baseline through Week 12 in the arhalofenate 600 mg group compared to the allopurinol 300 mg group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 600 mg group compared to placebo group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Time from baseline to onset of first flare for the arhalofenate 800 mg group compared to the allopurinol 300 mg group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Time from baseline to onset of first flare for the arhalofenate 600 mg group compared to the allopurinol 300 mg group", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "CymaBay Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CymaBay Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}